19937

524500

KILITCH

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

KILITCH DRUGS INDIA LTD Share Price Today

KILITCH DRUGS INDIA LTD is currently trading at ₹183.99, up by ₹2.44 from the previous close. The stock touched an intraday high of ₹187.19 and a low of ₹180.62 during the latest trading session. Over the past one year, KILITCH DRUGS INDIA LTD has delivered a loss of 18.56%, while the stock has gained 7.38% in the last one month.

KILITCH DRUGS INDIA LTD performance

Today’s low Today’s high
₹ 180.62 ₹ 187.19
₹ 182.69
52 week low 52 week high
₹ 117.25 ₹ 250.00
₹ 182.69
Open Price ₹ 182.00
Prev. Close ₹ 181.55
Volume (Shares) 123005.00
Total traded value ₹ 224.71
Upper Circuit ₹ 217.86
Lower Circuit ₹ 145.24
info

Investment Returns

Over 1 Month 7.38% Over 3 Months 13.64% Over 6 Months 9.51% Over 1 Year -18.56%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

KILITCH DRUGS INDIA LTD fundamentals


  • Market cap (Cr) 638.70
  • P/E Ratio (TTM) 19.53
  • Beta 1.01
  • Book Value / share 95.25
  • Return on equity 11.02%
  • EPS (TTM) 9.27
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 14.00
info icon alternate text
  • Market cap (Cr) 637.50
  • P/E Ratio (TTM) 19.53
  • Beta 0.78
  • Book Value / share 95.25
  • Return on equity 11.02%
  • EPS (TTM) 9.27
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 14.00
info icon alternate text

KILITCH DRUGS INDIA LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 71.97
Operating Expense 53.78
Net Profit 14.00
Net Profit Margin (%) 19.45
Earnings Per Share (EPS) 4.08
EBITDA 20.60
Effective Tax Rate (%) 27.57
Particulars DEC 2025 (Values in Cr)
Revenue 44.67
Operating Expense 40.11
Net Profit 4.89
Net Profit Margin (%) 10.94
Earnings Per Share (EPS) 2.74
EBITDA 7.33
Effective Tax Rate (%) 20.74
Particulars SEP 2025 (Values in Cr)
Revenue 37.81
Operating Expense 35.35
Net Profit 8.72
Net Profit Margin (%) 23.06
Earnings Per Share (EPS) 5.27
EBITDA 11.28
Effective Tax Rate (%) 13.50
Particulars JUN 2025 (Values in Cr)
Revenue 34.12
Operating Expense 31.64
Net Profit 4.79
Net Profit Margin (%) 14.03
Earnings Per Share (EPS) 2.98
EBITDA 7.07
Effective Tax Rate (%) 19.89
Particulars MAR 2025 (Values in Cr)
Revenue 56.30
Operating Expense 43.62
Net Profit 11.37
Net Profit Margin (%) 20.19
Earnings Per Share (EPS) 7.07
EBITDA 16.23
Effective Tax Rate (%) 24.13
Particulars MAR 2026 (Values in Cr)
Revenue 188.57
Operating Expense 160.87
Net Profit 32.40
Net Profit Margin (%) 17.18
Earnings Per Share (EPS) 9.57
EBITDA 46.27
Effective Tax Rate (%) 22.02
Particulars MAR 2025 (Values in Cr)
Revenue 181.59
Operating Expense 154.62
Net Profit 31.16
Net Profit Margin (%) 17.15
Earnings Per Share (EPS) 19.37
EBITDA 44.56
Effective Tax Rate (%) 23.42
Particulars MAR 2024 (Values in Cr)
Revenue 131.60
Operating Expense 114.44
Net Profit 17.57
Net Profit Margin (%) 13.35
Earnings Per Share (EPS) 11.03
EBITDA 26.50
Effective Tax Rate (%) 24.75
Particulars MAR 2023 (Values in Cr)
Revenue 117.78
Operating Expense 102.94
Net Profit 15.72
Net Profit Margin (%) 13.34
Earnings Per Share (EPS) 10.09
EBITDA 21.77
Effective Tax Rate (%) 19.17
Particulars MAR 2022 (Values in Cr)
Revenue 105.16
Operating Expense 95.78
Net Profit 10.53
Net Profit Margin (%) 10.01
Earnings Per Share (EPS) 6.76
EBITDA 15.55
Effective Tax Rate (%) 24.40
Particulars MAR 2025 (Values in Cr)
Book Value / Share 125.81
ROE % 11.68
ROCE % 15.57
Total Debt to Total Equity 0.21
EBITDA Margin 19.63
Particulars MAR 2024 (Values in Cr)
Book Value / Share 109.62
ROE % 8.28
ROCE % 13.30
Total Debt to Total Equity 0.16
EBITDA Margin 18.62
Particulars MAR 2023 (Values in Cr)
Book Value / Share 94.08
ROE % 5.70
ROCE % 10.24
Total Debt to Total Equity 0.15
EBITDA Margin 14.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 89.26
ROE % 4.03
ROCE % 6.34
Total Debt to Total Equity 0.13
EBITDA Margin 10.55
Particulars MAR 2021 (Values in Cr)
Book Value / Share 82.05
ROE % 2.41
ROCE % 3.51
Total Debt to Total Equity 0.11
EBITDA Margin 9.90
Particulars MAR 2025 (Values in Cr)
Book Value / Share 157.28
ROE % 11.02
ROCE % 13.14
Total Debt to Total Equity 0.17
EBITDA Margin 21.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 138.61
ROE % 8.39
ROCE % 10.74
Total Debt to Total Equity 0.13
EBITDA Margin 20.23
Particulars MAR 2023 (Values in Cr)
Book Value / Share 122.53
ROE % 8.41
ROCE % 9.89
Total Debt to Total Equity 0.11
EBITDA Margin 18.63
Particulars MAR 2022 (Values in Cr)
Book Value / Share 112.65
ROE % 6.18
ROCE % 7.82
Total Debt to Total Equity 0.10
EBITDA Margin 14.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 105.16
ROE % 3.32
ROCE % 4.20
Total Debt to Total Equity 0.09
EBITDA Margin 11.90
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 9.84
Total Assets 312.78
Total Liabilities 312.78
Total Equity 200.45
Share Outstanding 1
Price to Book Ratio 2.30
Return on Assets (%) 8.53
Return on Capital (%) 10.69
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 19.64
Total Assets 240.06
Total Liabilities 240.06
Total Equity 175.67
Share Outstanding 1
Price to Book Ratio 2.81
Return on Assets (%) 6.08
Return on Capital (%) 7.04
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 19.97
Total Assets 219.52
Total Liabilities 219.52
Total Equity 150.57
Share Outstanding 1
Price to Book Ratio 1.14
Return on Assets (%) 4.75
Return on Capital (%) 6.05
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 10.06
Total Assets 209.84
Total Liabilities 209.84
Total Equity 140.29
Share Outstanding 1
Price to Book Ratio 1.49
Return on Assets (%) 3.51
Return on Capital (%) 4.58
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 12.50
Total Assets 203.17
Total Liabilities 203.17
Total Equity 129.47
Share Outstanding 1
Price to Book Ratio 0.77
Return on Assets (%) 1.85
Return on Capital (%) 2.61
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 7.45
Total Assets 358.15
Total Liabilities 358.15
Total Equity 252.94
Share Outstanding 1
Price to Book Ratio 2.30
Return on Assets (%) 8.69
Return on Capital (%) 10.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 18.62
Total Assets 287.47
Total Liabilities 287.47
Total Equity 222.92
Share Outstanding 1
Price to Book Ratio 2.81
Return on Assets (%) 6.11
Return on Capital (%) 6.91
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.96
Total Assets 252.41
Total Liabilities 252.41
Total Equity 195.93
Share Outstanding 1
Price to Book Ratio 1.14
Return on Assets (%) 6.22
Return on Capital (%) 7.22
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.44
Total Assets 232.29
Total Liabilities 232.29
Total Equity 178.03
Share Outstanding 1
Price to Book Ratio 1.49
Return on Assets (%) 4.53
Return on Capital (%) 5.31
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.77
Total Assets 195.84
Total Liabilities 195.84
Total Equity 162.93
Share Outstanding 1
Price to Book Ratio 0.77
Return on Assets (%) 3.14
Return on Capital (%) 3.47
Particulars MAR 2025 (Values in Cr)
Net Income 34.47
Cash from Operations 26.01
Cash from Investing -39.94
Cash from Financing 13.24
Net change in Cash -9.16
Free Cash Flow 72.88
Particulars MAR 2024 (Values in Cr)
Net Income 19.35
Cash from Operations 5.50
Cash from Investing -8.15
Cash from Financing 8.80
Net change in Cash -0.88
Free Cash Flow 11.95
Particulars MAR 2023 (Values in Cr)
Net Income 12.01
Cash from Operations 6.91
Cash from Investing 7.91
Cash from Financing -0.71
Net change in Cash 9.78
Free Cash Flow 10.72
Particulars MAR 2022 (Values in Cr)
Net Income 9.61
Cash from Operations 8.31
Cash from Investing -15.25
Cash from Financing 7.02
Net change in Cash -2.43
Free Cash Flow 16.52
Particulars MAR 2021 (Values in Cr)
Net Income 5.11
Cash from Operations 46.67
Cash from Investing -37.56
Cash from Financing 1.61
Net change in Cash 9.70
Free Cash Flow 82.96
Particulars MAR 2025 (Values in Cr)
Net Income 40.68
Cash from Operations 23.70
Cash from Investing -41.42
Cash from Financing 15.65
Net change in Cash -10.54
Free Cash Flow 70.57
Particulars MAR 2024 (Values in Cr)
Net Income 23.35
Cash from Operations 4.45
Cash from Investing -8.70
Cash from Financing 11.40
Net change in Cash 0.11
Free Cash Flow 10.97
Particulars MAR 2023 (Values in Cr)
Net Income 19.44
Cash from Operations 10.42
Cash from Investing 6.24
Cash from Financing 3.04
Net change in Cash 15.38
Free Cash Flow 13.97
Particulars MAR 2022 (Values in Cr)
Net Income 13.92
Cash from Operations 7.74
Cash from Investing -16.08
Cash from Financing 7.55
Net change in Cash -3.32
Free Cash Flow 15.94
Particulars MAR 2021 (Values in Cr)
Net Income 7.50
Cash from Operations 7.13
Cash from Investing -5.34
Cash from Financing 2.27
Net change in Cash 3.05
Free Cash Flow 7.55
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 32.57 13.46 1.57 249.59 23.12 38.85
BLISS GVS PHARMA LTD. 474.55 38.52 4.21 5032.90 118.35 477.30
CIPLA LTD 1350.75 28.67 3.16 109119.71 1165.55 1672.20
FERMENTA BIOTECH LTD. 321.70 14.19 2.32 946.79 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 32.57 22.78 4.19 249.59 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 536.40 24.04 4.18 1550.77 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8520.60 111.28 24.40 21301.50 7630.00 10395.35
BLISS GVS PHARMA LTD. 474.55 51.19 4.35 5032.90 118.35 477.30

KILITCH DRUGS INDIA LTD shareholding pattern

Holding
36.22%
63.77%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

KILITCH DRUGS INDIA LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
182.69 0.62 redarrow
red-green-graph indicator
2 Bearish
14 Bullish
  • 5 Days 183.30
  • 26 Days 175.60
  • 10 Days 182.00
  • 50 Days 168.80
  • 12 Days 181.30
  • 100 Days 166.20
  • 20 Days 178.10
  • 200 Days 169.70
183.17 PIVOT
First Support 176.35 First Resistance 188.38 Second Support 171.14 Second Resistance 195.20 Third Support 164.32 Third Resistance 200.41
RSI 55.26 ADX 30.22 MACD 5.72 Williams % R -47.98 Commodity Channel Index (CCI) 22.61
Date 2026-06-17 Week 55303.00 Same Day 64023.00 Month 71838.00
1 Year 1.02 3 Year 0.81
Over 1 Month
7.38% down
Over 1 Year
-18.56% down
Over 3 Months
13.64% down
Over 3 Years
22.60% down
Over 6 Months
9.51% down
Over 5 Years
19.07% down

KILITCH DRUGS INDIA LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
20 Sep 2019 0.5 Final 24 Sep 2019 Equity shares
18 Sep 2018 0.5 Final 20 Sep 2018 Equity shares
24 Sep 2012 30.0 Special 25 Sep 2012 Equity shares
18 Aug 2011 1.0 Final 23 Aug 2011 Equity shares
14 Oct 2010 1.0 Final 15 Oct 2010 Equity shares
10 Sep 2009 1.0 Final 12 Sep 2009 Equity shares
10 Sep 2008 1.0 Final 12 Sep 2008 Equity shares
15 Nov 2007 1.0 Interim 16 Nov 2007 Equity shares
Ex-Date Ex-Bonus Ratio
24 Mar 2026 24 Mar 2026 1:1
Dividend date Dividend amount Dividend type Record date Instrument type
20 Sep 2019 0.5 Final 24 Sep 2019 Equity shares
18 Sep 2018 0.5 Final 20 Sep 2018 Equity shares
24 Sep 2012 30.0 Special 25 Sep 2012 Equity shares
18 Aug 2011 1.0 Final 23 Aug 2011 Equity shares
14 Oct 2010 1.0 Final 15 Oct 2010 Equity shares
10 Sep 2009 1.0 Final 12 Sep 2009 Equity shares
10 Sep 2008 1.0 Final 12 Sep 2008 Equity shares
15 Nov 2007 1.0 Interim 16 Nov 2007 Equity shares
Ex-Date Ex-Bonus Ratio
24 Mar 2026 24 Mar 2026 1:1

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Kilitch Drugs (India) Ltd?

Answer Field

Kilitch Drugs (India) Ltd share price is for NSE ₹ 183.99 & for BSE ₹ 183.00 as on Jun 18 2026 03:29 PM.

What is the Market Cap of Kilitch Drugs (India) Ltd Share?

Answer Field

The market cap of Kilitch Drugs (India) Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 18 2026 03:29 PM.

What is the 52 Week High and Low of Kilitch Drugs (India) Ltd?

Answer Field

The 52 Week High and Low of Kilitch Drugs (India) Ltd for NSE is ₹ 250.00 and ₹ 117.25 and for BSE is ₹ 245.00 and ₹ 121.10.

What is 1 year return for Kilitch Drugs (India) Ltd?

Answer Field

The 1 year returns on the stock has been -18.56%.

What is the P/E Ratio of Kilitch Drugs (India) Ltd Share?

Answer Field

As on Jun 18 2026 03:29 PM the price-to-earnings (PE) ratio for Kilitch Drugs (India) Ltd share is 19.53.

What is the PB ratio of Kilitch Drugs (India) Ltd Share?

Answer Field

As on Jun 18 2026 03:29 PM, the price-to-book (PB) ratio for Kilitch Drugs (India) Ltd share is 95.25.

How to Buy Kilitch Drugs (India) Ltd Share?

Answer Field

You can trade in Kilitch Drugs (India) Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Kilitch Drugs (India) Ltd Share on Bajaj Broking App?

Answer Field

To buy Kilitch Drugs (India) Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Kilitch Drugs (India) Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image
Get Free Demat Account*
+91
close-img
Authorise with OTP
Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|